此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

2017年7月18日 更新者：Marco Mielcarek、Fred Hutchinson Cancer Center

Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation

This phase II trial studies donor atorvastatin treatment for the prevention of severe acute graft-versus-host disease (GVHD) in patients undergoing myeloablative peripheral blood stem cell (PBSC) transplantation. Giving chemotherapy and total-body irradiation (TBI) before a donor PBSC transplant helps stop the growth of cancer cells. It may also prevent the patient's immune system reject the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving atorvastatin to the donor before transplant may prevent this from happening.

研究概览

地位

完全的

条件

干预/治疗

详细说明

PRIMARY OBJECTIVES:

I. To assess whether 2 weeks of donor statin treatment reduces the risk of severe acute GVHD.

SECONDARY OBJECTIVES:

I. To assess whether 2 weeks of statin treatment of normal PBSC donors is feasible, tolerable and safe.

OUTLINE:

Donors receive atorvastatin orally (PO) beginning on day -14 and continuing until the last day of stem cell collection.

研究类型

介入性

注册 (实际的)

83

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 美国
    • California
      • Stanford、California、美国、94305
        • Stanford University Hospitals and Clinics
    • Colorado
      • Denver、Colorado、美国、80907
        • Colorado Blood Cancer Institute
    • Washington
      • Seattle、Washington、美国、98109
        • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Human leukocyte antigen (HLA)-identical sibling donor
  • Myeloablative preparative regimen (i.e., >= TBI 12.0 Gy, >= busulfan (BU) 8.0 mg/kg PO, >= BU 6.4 mg/kg intravenously (IV), >= treosulfan 42 g/m^2 IV) according to investigational study or standard treatment plan; other "myeloablative" preparative regimens are acceptable as long as they are approved by the principal investigator or designee
  • Transplantation of PBSC
  • Cyclosporine (CSP)-based postgrafting immunosuppression
  • Willingness to give informed consent
  • DONOR: Age >= 18 years
  • DONOR: HLA genotypically identical sibling
  • DONOR: Willingness to give informed consent

Exclusion Criteria:

  • Nonmyeloablative preparative regimen
  • Participation in an investigational study that has acute GVHD as the primary endpoint
  • The allogeneic PBSC donor has a contraindication to statin treatment
  • DONOR: Age < 18 years
  • DONOR: Active liver disease (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] levels > 2 times the upper limit of normal [ULN])
  • DONOR: History of myopathy
  • DONOR: Hypersensitivity to atorvastatin
  • DONOR: Pregnancy
  • DONOR: Nursing mother
  • DONOR: Current serious systemic illness
  • DONOR: Concurrent treatment with strong inhibitors of hepatic cytochrome P450 (CYP) 3A4 (i.e. clarithromycin, erythromycin, protease inhibitors, azole antifungals)
  • DONOR: Current use of statin drug
  • DONOR: Failure to meet Fred Hutchinson Cancer Research Center (FHCRC) or local criteria for stem cell donation
  • DONOR: Total creatinine kinase > 2 times the ULN

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：支持治疗
  • 分配：不适用
  • 介入模型：单组作业
  • 屏蔽：无（打开标签）

武器和干预

参与者组/臂
干预/治疗
实验性的：Supportive care (donor statin treatment)
Donors receive atorvastatin calcium PO beginning on day -14 and continuing until the last day of stem cell collection.
药品：阿托伐他汀钙
给定采购订单
其他名称：
  • 立普妥
  • CI-981
程序：Allogeneic Hematopoietic Stem Cell Transplantation
Undergo myeloablative allogeneic PBSC transplant
其他名称：
  • 高等学校
  • HSCT
  • 同种异体干细胞移植
程序：Peripheral Blood Stem Cell Transplantation
Undergo myeloablative allogeneic PBSC transplant
其他名称：
  • PBPC移植
  • 外周血祖细胞移植
  • 外周干细胞支持
  • 外周血干细胞移植

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Grade 3-4 Acute GVHD
大体时间：First 100 days after transplant
Cumulative incidence rate of grade 3-4 acute GVHD with death as a completing risk, assessed at day 100 in the patients/recipients.
First 100 days after transplant

次要结果测量

结果测量
措施说明
大体时间
Chronic Extensive GVHD
大体时间：2 years post transplant
Cumulative incidence rate of chronic extensive GVHD with death as a competing risk, assessed at 2 years in the patients/recipients.
2 years post transplant
Disease-free Survival
大体时间：1 year after transplant
Evaluated as Kaplan-Meier estimate in the patients/recipients.
1 year after transplant
Grades II-IV Acute GVHD
大体时间：First 100 days after transplant
Cumulative incidence rate of grades II-IV acute GVHD with death as a competing risk, assessed at 100 days in the patients/recipients.
First 100 days after transplant
Non-relapse Mortality
大体时间：At day 100
Cumulative incidence rate of non-relapse mortalities, assessed at day 100 in the patients/recipients.
At day 100
Non-relapse Mortality
大体时间：At 1 year after HCT
Cumulative incidence rate of non-relapse mortalities, assessed at one year in the patients/recipients.
At 1 year after HCT
Overall Survival
大体时间：1 year after transplant
Determined and presented as Kaplan-Meier estimates, assessed at 1 year in the patients/recipients.
1 year after transplant
Proportion of Donors Who Have to Discontinue Atorvastatin Because of Toxicity
大体时间：Until completion of stem cell collection (on average 14 days)
Until completion of stem cell collection (on average 14 days)
Proportion of Patients Requiring Secondary Systemic Immunosuppressive Therapy
大体时间：First 100 days after transplant
First 100 days after transplant
Recurrent or Progressive Malignancy
大体时间：Up to 3 years
Cumulative incidence rate of recurrent or progressive malignancy with death as a competing risk, assessed at 3 years in the patients/recipients.
Up to 3 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Fred Hutchinson Cancer Center

合作者

National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2012年5月1日

初级完成 (实际的)

2015年9月1日

研究完成 (实际的)

2016年2月1日

研究注册日期

首次提交

2012年1月31日

首先提交符合 QC 标准的

2012年2月2日

首次发布 (估计)

2012年2月3日

研究记录更新

最后更新发布 (实际的)

2017年8月17日

上次提交的符合 QC 标准的更新

2017年7月18日

最后验证

2017年7月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 2545.00 (其他标识符：Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium)
  • P30CA015704 (美国 NIH 拨款/合同)
  • NCI-2011-03827 (注册表标识符：CTRP (Clinical Trial Reporting Program))
  • R01HL108307 (美国 NIH 拨款/合同)

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅